Stockholm - Delayed Quote SEK
Egetis Therapeutics AB (publ) (EGTX.ST)
At close: October 21 at 5:29 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Cash Flow
-246,600.0000
-278,400.0000
-173,500.0000
-130,100.0000
-134,639.0000
--
Investing Cash Flow
--
--
-1,700.0000
-6,000.0000
-59,543.0000
--
Financing Cash Flow
262,900.0000
458,900.0000
155,700.0000
-8,900.0000
228,405.0000
--
End Cash Position
195,500.0000
303,300.0000
127,700.0000
144,000.0000
287,850.0000
--
Capital Expenditure
--
--
--
-200.0000
-24.0000
--
Issuance of Capital Stock
171,900.0000
381,900.0000
177,400.0000
--
250,750.0000
--
Issuance of Debt
108,800.0000
108,800.0000
--
--
--
--
Repayment of Debt
-3,000.0000
-3,000.0000
-7,500.0000
-7,500.0000
--
--
Free Cash Flow
-246,600.0000
-278,400.0000
-173,500.0000
-130,300.0000
-134,663.0000
--
12/31/2019 - 4/7/2011
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
VICO.ST Vicore Pharma Holding AB (publ)
8.64
+0.23%
ATORX.ST Alligator Bioscience AB (publ)
1.2100
-4.12%
ELIC-TO2.ST Elicera Therapeutics AB
0.3000
-34.50%
APTA.ST Aptahem AB (publ)
1.5750
-3.96%
ACE.ST Ascelia Pharma AB (publ)
2.2050
0.00%
XBRANE.ST Xbrane Biopharma AB (publ)
0.2150
+19.44%
ELIC.ST Elicera Therapeutics AB (publ)
1.5100
-1.31%
BINV.ST BioInvent International AB (publ)
43.25
-3.46%
LYTIX.OL Lytix Biopharma AS
6.00
-1.64%
ONCO.ST Oncopeptides AB (publ)
2.0900
+0.24%